Member Info for chrishutch

Thanks! I still think with the 200ma, the trend line and support level just below price this is a good opportunity. I may even take a couple more while the opportunity to buy is here. News that will drive this much higher will come soon enough. So I am happy to be a little overexposed here.

Still here, still excited. The moment the last of the .45 stock is flipped this will really move up in my view. Buying now could be fruitful if you have patience to wait a tiny bit longer.

Looking at the criteria for the AI Awards that LabskinAI has been shortlisted for, it got me thinking about a new addition to my checklist for interest in companies to invest in.

I have all the normal stuff... are board invested....time till generating revenue....unique and commercially viable...etc..etc.. but I have added

'Can the brand, products or services change the world in some way?'

I doubt many companies can tick that box but for me I think SKIN might, just might be one of them!

I just got shares at 1.619 and the 200 day moving average is right there. Expect a bounce as there is very little vol in the dip.

I just took another 200k

Thanks.

https://pbs.twimg.com/media/EFLNFB1XYAEvIQC?format=jpg&name=900x900

From GB

This might help explain the USP for Labskin as presented to clients.

LabskinAI is an extension of the physical skin-test and experimentation processes using artificial intelligence to de-risk the innovation process cost of invention and improvement of therapeutic solutions for diseased skin. It allows industry to create, substantiate and deliver product development solutions safely, ethically and cost effectively to market by solving skin health problems that affect millions of men women and children worldwide. Offering innovators or emerging companies cost effective access to disease hosting living skin models, accredited laboratories, life science expertise and AI driven command and control models of the ideal microbiota balance.

It is the ability to clinically test multiple products, on multiple ‘cloned’ human microbiota, at the same time, reducing human volunteer recruitment costs, lowering clinical trial supervision and project management costs while accelerating the recovery of accurate and consistent results. This leads to “Quick Win, Fast Fail” product development cycles. LabskinAI creates an ecosystem to foster innovation and invention. As LabskinAI learns and adapts for new market segments, it brings new thinking to new product development processes where scientists are looking for new ways to treat damaged skin, and ultimately to personalise medical treatments.

Offering the market something it doesn’t have
Disruption is about the combination of technology and business model innovation: The combination of life science, digital technology and corporate innovation has already achieved a transformational turnaround of Integumen plc in less than 12 months. LabskinAI offers small, medium and large blue-chip corporations access to nimble end to end testing of skin care, health care, wound care, personal care and topical pharmaceutical products – all in one place. It reduces development time for research. It eliminates animal testing. It helps create efficient clinical trials – ALL driven and underwritten by data and the practical use of AI. It serves, what is clearly, an underserved market – SMEs.

Sorry to hear about your Thomas cook experience. I imagine that would cause some stress.

With regard to skin I think regardless of whether next news is large contract or not, the company has a big future.

I am holding a reasonable stake here now and am confident we will we see big returns over the next year. It is at that point where debts been paid down, revenue streams growing and opportunity presents itself.

I can’t think of an aim company to invest in that has more long term promise.

_Now might be a good time to load up! _

Gerard J Brandon
@gjbrandon

So much happening, just not in a position to announce.

https://twitter.com/gjbrandon/status/1176098235997478912?s=20

Very happy with my 300k top up this morning, happy to continue to take advantage here . Still catching up on all the developments over the last two weeks but.......

I thought the US News is huge and has been overlooked by the market in relation to where Integumen or rather Labskin and Labskin AI are positioned to exploit the ever-changing world of cosmetic and chemical testing.

EPA Administrator Andrew Wheeler said in a memo: “Scientific advancements exist today that allow us to better predict potential hazards for risk assessment purposes without the use of traditional methods that rely on animal testing.

Through scientific innovation and strategic partnerships, we can protect human health and the environment by using cutting-edge, ethically sound science in our decision-making that efficiently and cost-effectively evaluates potential effects without animal testing."

You can see where SKIN is pole positioned to fully take advantage of the fact the UK, EU and US if not the world are moving away from the science of yesterday and into a bright animal exploitation free future. With Labskins Lab-grown human skin and Artifical intelligence databases package it is streets ahead of the competition.

You have wonder how the big fish did not see this coming, where a small company like SKIN has blasted forward.

Combine this and the other news mentioned in my previous post regarding...

* Events in US and NEC completed and possible new client interest acquired
* Lucideon 3 Oct - Labskin will be there!
* 5th Annual European Microbiome Congress 13-14 Nov, London, UK - Labskin will be there!
* Microbiome R&D and Business Collaboration Forum – 18 – 20 May 2020, Rotterdam - Labskin will be there!
* Cosmoprof – 12-15 Mar 2020, Bologna Italy - Labskin will be there!
* Then there was US news re 'On the 10th September 2019, the United States Environmental Protection Agency’s (EPA) Administrator Mr Andrew Wheeler signed a new directive to prioritise efforts to reduce and eliminate animal testing across the United States of America.'
* Rinocloud Shortlisted for AI Awards Ireland 2019 - WOW!

And you can see the word is getting out, the contracts will start to roll in and the AI will be getting a lot more attention. Investors will be paying a lot more for shares in the not to distance future as soon as contracts or news lands the price will not be here anymore.

Back from holiday and very happy to see JAN making moves on the dance floor.

The 300k buy is mine

I see the company has been busy!

Since the breakthrough cloning study success and ability to test multiple trail subjects in parallel reducing the need further for human subjects and making animal test subjects seem a barbaric thing of the past.

* Events in US and NEC completed and possible new client interest acquired
* Lucideon 3 Oct - Labskin will be there!
* 5th Annual European Microbiome Congress 13-14 Nov, London, UK - Labskin will be there!
* Microbiome R&D and Business Collaboration Forum – 18 – 20 May 2020, Rotterdam - Labskin will be there!
* Cosmoprof – 12-15 Mar 2020, Bologna Italy - Labskin will be there!
* Then there was US news re 'On the 10th September 2019, the United States Environmental Protection Agency’s (EPA) Administrator Mr Andrew Wheeler signed a new directive to prioritise efforts to reduce and eliminate animal testing across the United States of America.'
* Rinocloud Shortlisted for AI Awards Ireland 2019 - WOW!
* The share price is an absolute gift down here.

The company is progressing so fast with so many potential revenue streams already generating income whilst blasting the technological and scientific socks off the competitors!

Has to be a buy.

Hi Gidget, Yes got back on Sunday morning thank you, had a really nice break and feel relaxed and ready for another few months of market fun!

Please spend a bit of time looking at the company it is not a rainbow chasing share, it is a solid business model which is being noticed and respected by huge companies. But most importantly....

This is a revenue-making business already, people seem to have missed this. It has a large pipeline of orders and is growing to meet demand from top ten companies. They are effectively cherry-picking the big players rather than just taking anyone who comes along but don't for a second think the demand from both big and small organizations is not there. It is and will only continue to grow exponentially.

SKIN will move towards 30m to 50m within a year as those bigger contracts start rolling in.

Don't miss out on a good opportunity cause you would rather read boards than do a little research.

Happy to see this starting to move up. Looking forward to a break into the 2p + area.

Nice one.

Price was 1.8 on my phone when I typed that. I also meant around the 1.8 to 2p area.

What I was saying is that it only takes one or two big deals and this really will move.

Looks fairly valued to me price floats around. Some have sold and moved on just as the story start d to get exciting. Lot of one off costs, debt paid down, legacy tax and fees cleared up. As well as equipment and lab expansion costs. These will not be on going.

So will be easier to grow from here. Especially as the parts of the business that were not performing have been disposed of. Leaving the team to improve and develop the cream of the crop.

The company is progressing steady and looks very promising to me. Sure I want the price higher but it will get back up this much I am certain of. So as the deals are done and relationships made we are fortunate enough to be getting shares down here.

One or two big contracts, partnerships or agreements and this price is gone. I also believe that the company is well positioned and able to win these bigger contracts. It is management I am comfortable leaving to my money with.